Effectiveness and Prognostic Factors of Apatinib Treatment in Patients with Recurrent or Advanced Cervical Carcinoma: A Retrospective Study

Overview

Journal Cancer Med

Specialty Oncology

Date 2021 May 14

PMID 33987959

Citations 5

Authors

Hui Yang

Min Chen

Zijie Mei

Conghua Xie

Yunfeng Zhou

Hui Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Apatinib is an oral anti-angiogenic drug, its efficacy and prognosis in cervical carcinoma are unclear. This study evaluates the effectiveness and prognostic factors of apatinib in the treatment of recurrent or advanced cervical carcinoma.

Methods: Patients with recurrent or advanced cervical cancer, who agreed to take apatinib, were recruited into this single-center and retrospective study, and administrated apatinib with or without combination of chemo- or radio-therapy until progressive disease (PD) or unacceptable toxicity.

Results: From March 2017 to February 2019, 53 patients were reviewed. Among them, 2 (3.77%) patients occurred complete response, 16 (30.19%) patients showed partial response, 27 (50.95%) patients had stable disease, and 8 (15.09%) patients had PD. The objective response rate and disease control rate (DCR) of these patients were 33.96% and 84.91%, respectively. The DCR of patients younger than 50, nonsquamous carcinoma, first-line apatinib therapy, combined radiotherapy, lesions within radiation field, surgical history, and Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 were significantly higher than other patients (p < 0.05). The median progression-free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.43-7.57) and 8.0 months (95% CI: 6.52-9.48), respectively. The univariable and multivariable analysis showed that the patients with an ECOG performance status score of 2 and further line therapy were associated with poor prognosis in both PFS and OS (PFS: HR =8.35, p = 0.000; HR =6.66, p = 0.001; OS: HR = 7.40, p = 0.000; HR = 3.24, p = 0.039), respectively. The most common adverse effects (AEs) were hand-foot syndrome (35.58%), hypertension (18.87%) and fatigue (15.09%). No grade 3 AEs and drug-related death occurred.

Conclusion: The efficacy and prognosis of patients who are in good general condition and first-line apatinib combination therapy may be better than other patients. But further phase III clinical trials should be taken to prove this hypothesis.

Citing Articles

Known and unknown: Exosome secretion in tumor microenvironment needs more exploration.

Huang M, Ji J, Xu X, Jin D, Wu T, Lin R Genes Dis. 2024; 12(1):101175.

PMID: 39524543 PMC: 11550746. DOI: 10.1016/j.gendis.2023.101175.

Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.

Ren Y, Wang T, Cheng X, Ke G, Huang Y, Yang H Ann Transl Med. 2023; 11(2):106.

PMID: 36819505 PMC: 9929780. DOI: 10.21037/atm-22-6463.

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients.

Huang D, He Q, Zhai L, Shen J, Jing F, Chen H Front Pharmacol. 2022; 13:843905.

PMID: 36034824 PMC: 9403417. DOI: 10.3389/fphar.2022.843905.

A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.

Yang H, Sun S, Mei Z, Xiang Q, Yang C, Chen M Drug Des Devel Ther. 2021; 15:4665-4674.

PMID: 34815663 PMC: 8605803. DOI: 10.2147/DDDT.S335870.

Cohort Profile: Chinese Cervical Cancer Clinical Study.

Zhang X, Li Z, Sun L, Liu P, Li Z, Li P Front Oncol. 2021; 11:690275.

PMID: 34222018 PMC: 8250135. DOI: 10.3389/fonc.2021.690275.

References

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

Schefter T, Winter K, Kwon J, Stuhr K, Balaraj K, Yaremko B . A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012; 83(4):1179-84. DOI: 10.1016/j.ijrobp.2011.10.060. View

Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le A . Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res. 2007; 13(9):2568-76. DOI: 10.1158/1078-0432.CCR-06-2704. View

Qiu H, Li J, Liu Q, Tang M, Wang Y . Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle. 2018; 17(10):1235-1244. PMC: 6110593. DOI: 10.1080/15384101.2018.1471315. View

Gourley C . Apatinib and etoposide: surprising efficacy of an oral combination. Lancet Oncol. 2018; 19(9):1146-1147. DOI: 10.1016/S1470-2045(18)30444-3. View

Schefter T, Winter K, Kwon J, Stuhr K, Balaraj K, Yaremko B . RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2013; 88(1):101-5. DOI: 10.1016/j.ijrobp.2013.10.022. View

Liang L, Wang L, Zhu P, Xia Y, Qiao Y, Hui K . Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report. Medicine (Baltimore). 2018; 96(47):e8725. PMC: 5708962. DOI: 10.1097/MD.0000000000008725. View

Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, Balligand J . Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res. 2003; 63(5):1012-9. View

Monk B, Sill M, McMeekin D, Cohn D, Ramondetta L, Boardman C . Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009; 27(28):4649-55. PMC: 2754911. DOI: 10.1200/JCO.2009.21.8909. View

10.

Song C, LEVITT S . Effect of x irradiation on vascularity of normal tissues and experimental tumor. Radiology. 1970; 94(2):445-7. DOI: 10.1148/94.2.445. View

11.

Zhang L, Chen L, Yu H . Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients. Invest New Drugs. 2019; 38(4):1186-1191. DOI: 10.1007/s10637-019-00858-5. View

12.

Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Jahan I, Alam S . Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers. J Biomed Sci. 2006; 13(6):825-32. DOI: 10.1007/s11373-006-9114-6. View

13.

Xiao Y, Cheng H, Wang L, Yu X . Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study. J Gynecol Oncol. 2019; 31(1):e2. PMC: 6918889. DOI: 10.3802/jgo.2020.31.e2. View

14.

Chen C, Qin S, Li Z, Luo X, Zhang Y, Zhang J . A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix. Onco Targets Ther. 2019; 12:5805-5811. PMC: 6643513. DOI: 10.2147/OTT.S212536. View

15.

Guitarte C, Alagkiozidis I, Mize B, Stevens E, Salame G, Lee Y . Glassy cell carcinoma of the cervix: a systematic review and meta-analysis. Gynecol Oncol. 2014; 133(2):186-91. DOI: 10.1016/j.ygyno.2014.01.048. View

16.

Li N, Wang Z, Yuan G, Sun Y, Zhang R, Li X . An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study. J Oncol. 2020; 2020:3852373. PMC: 7327550. DOI: 10.1155/2020/3852373. View

17.

Guo Q, Sun Y, Kong E, Rao L, Chen J, Wu Q . Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study. Medicine (Baltimore). 2020; 99(11):e19372. PMC: 7220314. DOI: 10.1097/MD.0000000000019372. View

18.

Li J, Jia Y, Gao Y, Chang Z, Han H, Yan J . Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther. 2019; 12:2577-2583. PMC: 6459155. DOI: 10.2147/OTT.S191736. View

19.

Lara P, Lloret M, Clavo B, Apolinario R, Henriquez-Hernandez L, Bordon E . Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat Oncol. 2009; 4:29. PMC: 2728103. DOI: 10.1186/1748-717X-4-29. View

20.

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P . Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350(9077):535-40. DOI: 10.1016/S0140-6736(97)02250-2. View